|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gridelli C, Rossi A, Carbone DP, Guarize
J, Karachaliou N, Mok T, Petrella F, Spaggiari L and Rosell R:
Non-small-cell lung cancer. Nat Rev Dis Primers. 1:150092015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng YW, Li RM, Zhang XW and Ren XB:
Current adoptive immunotherapy in non-small cell lung cancer and
potential influence of therapy outcome. Cancer Invest. 31:197–205.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bagchi S, Yuan R and Engleman EG: Immune
checkpoint inhibitors for the treatment of cancer: Clinical impact
and mechanisms of response and resistance. Annu Rev Pathol.
16:223–249. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Somasundaram A and Burns TF: The next
generation of immunotherapy: Keeping lung cancer in check. J
Hematol Oncol. 10:872017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi T, Ma Y, Yu L, Jiang J, Shen S, Hou Y
and Wang T: Cancer immunotherapy: A focus on the regulation of
immune checkpoints. Int J Mol Sci. 19:13892018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Joller N and Kuchroo VK: Tim-3, Lag-3, and
TIGIT. Curr Top Microbiol Immunol. 410:127–156. 2017.PubMed/NCBI
|
|
10
|
Tivol EA, Borriello F, Schweitzer AN,
Lynch WP, Bluestone JA and Sharpe AH: Loss of CTLA-4 leads to
massive lymphoproliferation and fatal multiorgan tissue
destruction, revealing a critical negative regulatory role of
CTLA-4. Immunity. 3:541–547. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leach DR, Krummel MF and Allison JP:
Enhancement of antitumor immunity by CTLA-4 blockade. Science.
271:1734–1736. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ostrov DA, Shi W, Schwartz JC, Almo SC and
Nathenson SG: Structure of murine CTLA-4 and its role in modulating
T cell responsiveness. Science. 290:816–819. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iida T, Ohno H, Nakaseko C, Sakuma M,
Takeda-Ezaki M, Arase H, Kominami E, Fujisawa T and Saito T:
Regulation of cell surface expression of CTLA-4 by secretion of
CTLA-4-containing lysosomes upon activation of CD4+ T
cells. J Immunol. 165:5062–5068. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharpe AH and Freeman GJ: The B7-CD28
superfamily. Nat Rev Immunol. 2:116–126. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Buchbinder EI and Desai A: CTLA-4 and PD-1
pathways: Similarities, differences, and implications of their
inhibition. Am J Clin Oncol. 39:98–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
de Miguel M and Calvo E: Clinical
challenges of immune checkpoint inhibitors. Cancer Cell.
38:326–333. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamazaki T, Akiba H, Iwai H, Matsuda H,
Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al:
Expression of programmed death 1 ligands by murine T cells and APC.
J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yokosuka T, Takamatsu M,
Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M and Saito T:
Programmed cell death 1 forms negative costimulatory microclusters
that directly inhibit T cell receptor signaling by recruiting
phosphatase SHP2. J Exp Med. 209:1201–1217. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O'Kane GM, Labbé C, Doherty MK, Young K,
Albaba H and Leighl NB: Monitoring and management of immune-related
adverse events associated with programmed cell death protein-1 axis
inhibitors in lung cancer. Oncologist. 22:70–80. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Ma Q, Yao R and Liu J: Current
status and development of anti-PD-1/PD-L1 immunotherapy for lung
cancer. Int Immunopharmacol. 79:1060882020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huard B, Mastrangeli R, Prigent P,
Bruniquel D, Donini S, El-Tayar N, Maigret B, Dréano M and Triebel
F: Characterization of the major histocompatibility complex class
II binding site on LAG-3 protein. Proc Natl Acad Sci USA.
94:5744–5749. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Anderson AC, Joller N and Kuchroo VK:
Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized
functions in immune regulation. Immunity. 44:989–1004. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Byun HJ, Jung WW, Lee DS, Kim S, Kim SJ,
Park CG, Chung HY and Chun T: Proliferation of activated
CD1d-restricted NKT cells is down-modulated by lymphocyte
activation gene-3 signaling via cell cycle arrest in S phase. Cell
Biol Int. 31:257–262. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maruhashi T, Okazaki IM, Sugiura D,
Takahashi S, Maeda TK, Shimizu K and Okazaki T: LAG-3 inhibits the
activation of CD4+ T cells that recognize stable pMHCII
through its conformation-dependent recognition of pMHCII. Nat
Immunol. 19:1415–1426. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Sanmamed MF, Datar I, Su TT, Ji L,
Sun J, Chen L, Chen Y, Zhu G, Yin W, et al: Fibrinogen-like protein
1 is a major immune inhibitory ligand of LAG-3. Cell.
176:334–347.e12. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kouo T, Huang L, Pucsek AB, Cao M, Solt S,
Armstrong T and Jaffee E: Galectin-3 shapes antitumor immune
responses by suppressing CD8+ T cells via LAG-3 and
inhibiting expansion of plasmacytoid dendritic cells. Cancer
Immunol Res. 3:412–423. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang R, Rangachari M and Kuchroo VK:
Tim-3: A co-receptor with diverse roles in T cell exhaustion and
tolerance. Semin Immunol. 42:1013022019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Acharya N, Sabatos-Peyton C and Anderson
AC: Tim-3 finds its place in the cancer immunotherapy landscape. J
Immunother Cancer. 8:e0009112020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Das M, Zhu C and Kuchroo VK: Tim-3 and its
role in regulating anti-tumor immunity. Immunol Rev. 276:97–111.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang YH, Zhu C, Kondo Y, Anderson AC,
Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, et
al: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.
Nature. 517:386–390. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sakuishi K, Apetoh L, Sullivan JM, Blazar
BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways
to reverse T cell exhaustion and restore anti-tumor immunity. J Exp
Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Stanietsky N, Simic H, Arapovic J, Toporik
A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al:
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell
cytotoxicity. Proc Natl Acad Sci USA. 106:17858–17863. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yu X, Harden K, Gonzalez LC, Francesco M,
Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H, et al: The
surface protein TIGIT suppresses T cell activation by promoting the
generation of mature immunoregulatory dendritic cells. Nat Immunol.
10:48–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boles KS, Vermi W, Facchetti F, Fuchs A,
Wilson TJ, Diacovo TG, Cella M and Colonna M: A novel molecular
interaction for the adhesion of follicular CD4 T cells to
follicular DC. Eur J Immunol. 39:695–703. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He Y, Peng H, Sun R, Wei H, Ljunggren HG,
Yokoyama WM and Tian Z: Contribution of inhibitory receptor TIGIT
to NK cell education. J Autoimmun. 81:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Johnston RJ, Comps-Agrar L, Hackney J, Yu
X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, et al:
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T
cell effector function. Cancer Cell. 26:923–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Herzberg B, Campo MJ and Gainor JF: Immune
checkpoint inhibitors in non-small cell lung cancer. Oncologist.
22:81–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang P, Xiong X, Rolfo C, Du X, Zhang Y,
Yang H, Russo A, Devenport M, Zhou P, Liu Y and Zheng P: Mechanism-
and immune landscape-based ranking of therapeutic responsiveness of
22 major human cancers to next generation anti-CTLA-4 antibodies.
Cancers (Basel). 12:2842020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kazandjian D, Suzman DL, Blumenthal G,
Mushti S, He K, Libeg M, Keegan P and Pazdur R: FDA approval
summary: Nivolumab for the treatment of metastatic non-small cell
lung cancer with progression on or after platinum-based
chemotherapy. Oncologist. 21:634–642. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Akinleye A and Rasool Z: Immune checkpoint
inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol.
12:922019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mathew M, Enzler T, Shu CA and Rizvi NA:
Combining chemotherapy with PD-1 blockade in NSCLC. Pharmacol Ther.
186:130–137. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Cyriac G and Gandhi L: Emerging biomarkers
for immune checkpoint inhibition in lung cancer. Semin Cancer Biol.
52:(Pt 2):269–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yarchoan M, Albacker LA, Hopkins AC,
Montesion M, Murugesan K, Vithayathil TT, Zaidi N, Azad NS, Laheru
DA, Frampton GM and Jaffee EM: PD-L1 expression and tumor
mutational burden are independent biomarkers in most cancers. JCI
Insight. 4:e1269082019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pai-Scherf L, Blumenthal GM, Li H,
Subramaniam S, Mishra-Kalyani PS, He K, Zhao H, Yu J, Paciga M,
Goldberg KB, et al: FDA approval summary: Pembrolizumab for
treatment of metastatic non-small cell lung cancer: First-line
therapy and beyond. Oncologist. 22:1392–1399. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Abdel-Rahman O: Correlation between PD-L1
expression and outcome of NSCLC patients treated with
anti-PD-1/PD-L1 agents: A meta-analysis. Crit Rev Oncol Hematol.
101:75–85. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Davis AA and Patel VG: The role of PD-L1
expression as a predictive biomarker: An analysis of all US Food
and Drug Administration (FDA) approvals of immune checkpoint
inhibitors. J Immunother Cancer. 7:2782019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Paver EC, Cooper WA, Colebatch AJ,
Ferguson PM, Hill SK, Lum T, Shin JS, O'Toole S, Anderson L,
Scolyer RA and Gupta R: Programmed death ligand-1 (PD-L1) as a
predictive marker for immunotherapy in solid tumours: A guide to
immunohistochemistry implementation and interpretation. Pathology.
53:141–156. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fournel L, Wu Z, Stadler N, Damotte D,
Lococo F, Boulle G, Ségal-Bendirdjian E, Bobbio A, Icard P,
Trédaniel J, et al: Cisplatin increases PD-L1 expression and
optimizes immune check-point blockade in non-small cell lung
cancer. Cancer Lett. 464:5–14. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Velcheti V, Schalper KA, Carvajal DE,
Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L
and Rimm DL: Programmed death ligand-1 expression in non-small cell
lung cancer. Lab Invest. 94:107–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ilie M, Long-Mira E, Bence C, Butori C,
Lassalle S, Bouhlel L, Fazzalari L, Zahaf K, Lalvée S, Washetine K,
et al: Comparative study of the PD-L1 status between surgically
resected specimens and matched biopsies of NSCLC patients reveal
major discordances: A potential issue for anti-PD-L1 therapeutic
strategies. Ann Oncol. 27:147–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Rimm DL, Han G, Taube JM, Yi ES, Bridge
JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, et al: A
prospective, multi-institutional, pathologist-based assessment of 4
immunohistochemistry assays for PD-L1 expression in non-small cell
lung cancer. JAMA Oncol. 3:1051–1058. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Büttner R, Gosney JR, Skov BG, Adam J,
Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F,
Penault-Llorca F, et al: Programmed death-ligand 1
immunohistochemistry testing: A review of analytical assays and
clinical implementation in non-small-cell lung cancer. J Clin
Oncol. 35:3867–3876. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Vilimas T: Measuring tumor mutational
burden using whole-exome sequencing. Methods Mol Biol. 2055:63–91.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ready N, Hellmann MD, Awad MM, Otterson
GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M,
et al: First-line nivolumab plus ipilimumab in advanced
non-small-cell lung cancer (CheckMate 568): Outcomes by programmed
death ligand 1 and tumor mutational burden as biomarkers. J Clin
Oncol. 37:992–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Merino DM, McShane LM, Fabrizio D, Funari
V, Chen SJ, White JR, Wenz P, Baden J, Barrett JC, Chaudhary R, et
al: Establishing guidelines to harmonize tumor mutational burden
(TMB): In silico assessment of variation in TMB quantification
across diagnostic platforms: Phase I of the Friends of cancer
research TMB harmonization project. J Immunother Cancer.
8:e0001472020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wojas-Krawczyk K, Kalinka E, Grenda A,
Krawczyk P and Milanowski J: Beyond PD-L1 markers for lung cancer
immunotherapy. Int J Mol Sci. 20:19152019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Rizvi H, Sanchez-Vega F, La K, Chatila W,
Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N,
et al: Molecular determinants of response to anti-programmed cell
death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in
patients with non-small-cell lung cancer profiled with targeted
next-generation sequencing. J Clin Oncol. 36:633–641. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Doostparast Torshizi A and Wang K:
Next-generation sequencing in drug development: Target
identification and genetically stratified clinical trials. Drug
Discov Today. 23:1776–1783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sa H, Ma K, Gao Y and Wang D: Predictive
value of tumor mutation burden in immunotherapy for lung cancer.
Zhongguo Fei Ai Za Zhi. 22:380–384. 2019.(In Chinese). PubMed/NCBI
|
|
66
|
Pisapia P, Malapelle U and Troncone G:
Liquid biopsy and lung cancer. Acta Cytol. 63:489–496. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gandara DR, Paul SM, Kowanetz M,
Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G,
Malboeuf C, et al: Blood-based tumor mutational burden as a
predictor of clinical benefit in non-small-cell lung cancer
patients treated with atezolizumab. Nat Med. 24:1441–1448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nie W, Qian J, Xu MD, Gu K, Qian FF, Hu
MJ, Lu J, Gan L, Zhang XY, Cao SH, et al: A non-linear association
between blood tumor mutation burden and prognosis in NSCLC patients
receiving atezolizumab. Oncoimmunology. 9:17310722020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Chen YT, Seeruttun SR, Wu XY and Wang ZX:
Maximum somatic allele frequency in combination with blood-based
tumor mutational burden to predict the efficacy of atezolizumab in
advanced non-small cell lung cancer: A pooled analysis of the
randomized POPLAR and OAK studies. Front Oncol. 9:14322019.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ,
Xie CM and Hu QG: Prognostic and predictive value of
tumor-infiltrating lymphocytes for clinical therapeutic research in
patients with non-small cell lung cancer. Oncotarget.
7:13765–13781. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Bodor JN, Boumber Y and Borghaei H:
Biomarkers for immune checkpoint inhibition in non-small cell lung
cancer (NSCLC). Cancer. 126:260–270. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hurkmans DP, Kuipers ME, Smit J, van
Marion R, Mathijssen RHJ, Postmus PE, Hiemstra PS, Aerts JGJV, von
der Thüsen JH and van der Burg SH: Tumor mutational load,
CD8+ T cells, expression of PD-L1 and HLA class I to
guide immunotherapy decisions in NSCLC patients. Cancer Immunol
Immunother. 69:771–777. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
O'Donnell JS, Long GV, Scolyer RA, Teng MW
and Smyth MJ: Resistance to PD1/PDL1 checkpoint inhibition. Cancer
Treat Rev. 52:71–81. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Memon H and Patel BM: Immune checkpoint
inhibitors in non-small cell lung cancer: A bird's eye view. Life
Sci. 233:1167132019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wang S, He Z, Wang X, Li H and Liu XS:
Antigen presentation and tumor immunogenicity in cancer
immunotherapy response prediction. Elife. 8:e490202019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al: Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Martin AM, Nirschl TR, Nirschl CJ,
Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders
RA, DeMarzo AM and Drake CG: Paucity of PD-L1 expression in
prostate cancer: Innate and adaptive immune resistance. Prostate
Cancer Prostatic Dis. 18:325–332. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Leclerc M, Mezquita L, Guillebot De
Nerville G, Tihy I, Malenica I, Chouaib S and Mami-Chouaib F:
Recent advances in lung cancer immunotherapy: Input of T-cell
epitopes associated with impaired peptide processing. Front
Immunol. 10:15052019. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Garrido C, Paco L, Romero I, Berruguilla
E, Stefansky J, Collado A, Algarra I, Garrido F and Garcia-Lora AM:
MHC class I molecules act as tumor suppressor genes regulating the
cell cycle gene expression, invasion and intrinsic tumorigenicity
of melanoma cells. Carcinogenesis. 33:687–693. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wang X, Schoenhals JE, Li A, Valdecanas
DR, Ye H, Zang F, Tang C, Tang M, Liu CG, Liu X, et al: Suppression
of type I IFN signaling in tumors mediates resistance to Anti-PD-1
treatment that can be overcome by radiotherapy. Cancer Res.
77:839–850. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Thommen DS, Schreiner J, Müller P, Herzig
P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, et al:
Progression of lung cancer is associated with increased dysfunction
of T cells defined by coexpression of multiple inhibitory
receptors. Cancer Immunol Res. 3:1344–1355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Curigliano G, Gelderblom H, Mach N, Doi T,
Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, et
al: Phase I/Ib clinical trial of sabatolimab, an Anti-TIM-3
antibody, alone and in combination with spartalizumab, an Anti-PD-1
antibody, in advanced solid tumors. Clin Cancer Res. 27:3620–3629.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Koyama S, Akbay EA, Li YY, Herter-Sprie
GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ,
Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade
is associated with upregulation of alternative immune checkpoints.
Nat Commun. 7:105012016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hellmann MD, Rizvi NA, Goldman JW,
Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ,
Juergens RA, et al: Nivolumab plus ipilimumab as first-line
treatment for advanced non-small-cell lung cancer (CheckMate 012):
Results of an open-label, phase 1, multicohort study. Lancet Oncol.
18:31–41. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus Ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Bylicki O, Barazzutti H, Paleiron N,
Margery J, Assié JB and Chouaïd C: First-line treatment of
non-small-cell lung cancer (NSCLC) with immune checkpoint
inhibitors. BioDrugs. 33:159–171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Davis M, Conlon K, Bohac GC, Barcenas J,
Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y and Plate JM: Effect
of pemetrexed on innate immune killer cells and adaptive immune T
cells in subjects with adenocarcinoma of the pancreas. J
Immunother. 35:629–640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Javeed A, Ashraf M, Riaz A, Ghafoor A,
Afzal S and Mukhtar MM: Paclitaxel and immune system. Eur J Pharm
Sci. 38:283–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Borghaei H, Langer CJ, Gadgeel S,
Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins
RG, Stevenson JP, Jalal SI, et al: 24-Month overall survival from
KEYNOTE-021 Cohort G: Pemetrexed and carboplatin with or without
pembrolizumab as first-line therapy for advanced nonsquamous
non-small cell lung cancer. J Thorac Oncol. 14:124–129. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Aupérin A, Le Péchoux C, Rolland E, Curran
WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus
R, et al: Meta-analysis of concomitant versus sequential
radiochemotherapy in locally advanced non-small-cell lung cancer. J
Clin Oncol. 28:2181–2190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jarosz-Biej M, Smolarczyk R, Cichoń T and
Kułach N: Tumor microenvironment as a ‘game changer’ in cancer
radiotherapy. Int J Mol Sci. 20:32122019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Barker HE, Paget JT, Khan AA and
Harrington KJ: The tumour microenvironment after radiotherapy:
Mechanisms of resistance and recurrence. Nat Rev Cancer.
15:409–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou
F and Zhou C: Combined radiotherapy and anti-PD-L1 antibody
synergistically enhances antitumor effect in non-small cell lung
cancer. J Thorac Oncol. 12:1085–1097. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Theelen WSME, Peulen HMU, Lalezari F, van
der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I,
Niemeijer AN, de Langen AJ, et al: Effect of pembrolizumab after
stereotactic body radiotherapy vs pembrolizumab alone on tumor
response in patients with advanced non-small cell lung cancer:
Results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA
Oncol. 5:1276–1282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Li JX, Huang JM, Jiang ZB, Li RZ, Sun A,
Lai-Han Leung E and Yan PY: Current clinical progress of PD-1/PD-L1
immunotherapy and potential combination treatment in non-small cell
lung cancer. Integr Cancer Ther. 18:15347354198900202019.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Habas K, Nganwuchu C, Shahzad F, Gopalan
R, Haque M, Rahman S, Majumder AA and Nasim T: Resolution of
coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther.
18:1201–1211. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
DU HZ, Hou XY, Miao YH, Huang BS and Liu
DH: Traditional Chinese Medicine: An effective treatment for 2019
novel coronavirus pneumonia (NCP). Chin J Nat Med. 18:206–210.
2020.PubMed/NCBI
|
|
102
|
Wood SL, Pernemalm M, Crosbie PA and
Whetton AD: The role of the tumor-microenvironment in lung
cancer-metastasis and its relationship to potential therapeutic
targets. Cancer Treat Rev. 40:558–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wang Y, Zhang Q, Chen Y, Liang CL, Liu H,
Qiu F and Dai Z: Antitumor effects of immunity-enhancing
traditional Chinese medicine. Biomed Pharmacother. 121:1095702020.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Liao CH, Yong CY, Lai GM, Chow JM, Cheng
CF, Fang CL, Lin PC, Chang CL, Zheng YM, Chuang SE, et al:
Astragalus polysaccharide (PG2) suppresses macrophage
migration inhibitory factor and aggressiveness of lung
adenocarcinoma cells. Am J Chin Med. 48:1491–1509. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li W, Hu X, Wang S, Jiao Z, Sun T, Liu T
and Song K: Characterization and anti-tumor bioactivity of
astragalus polysaccharides by immunomodulation. Int J Biol
Macromol. 145:985–997. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Bamodu OA, Kuo KT, Wang CH, Huang WC, Wu
ATH, Tsai JT, Lee KY, Yeh CT and Wang LS: Astragalus
polysaccharides (PG2) enhances the M1 polarization of macrophages,
functional maturation of dendritic cells, and T cell-mediated
anticancer immune responses in patients with lung cancer.
Nutrients. 11:22642019. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang HB, Zheng QY, Qian DH, Fang J and Ju
DW: Effects of Phytolacca acinosa polysaccharides I on
immune function in mice. Zhongguo Yao Li Xue Bao. 14:243–246.
1993.PubMed/NCBI
|
|
108
|
Chen Y, Wang Y, Xu L, Zhu W, Xu C, Xu M,
Guo L, Hu W, Xu D, Jing R, et al: Influence of total glucosides of
paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome. Int
J Rheum Dis. 22:200–206. 2019. View Article : Google Scholar : PubMed/NCBI
|
